Peptomyc announces first patient dosed in Phase 2 clinical trial of OMO-103 in advanced osteosarcoma 11 / 03 / 25| Read More
Peptomyc announces the beginning of a Phase 2 clinical trial of OMO-103 in advanced osteosarcoma 16 / 01 / 25| Read More
Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients 09 / 12 / 24| Read More
Peptomyc S.L. Expands its Patent Portfolio with a Patent Grant in Hong Kong for its Methods and Composition for the Treatment of Cancer 19 / 08 / 24| Read More
Peptomyc S.L. Expands Patent Portfolio with European and Indian Patent Grant for its Methods and Composition for the Treatment of Cancer 15 / 07 / 24| Read More
Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial 06 / 02 / 24| Read More
The spin-off Peptomyc and VHIO awarded €4 million from the Spanish Ministry of Science and Innovation to advance the clinical development of the first direct MYC inhibitor 20 / 12 / 23| Read More
